PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (NCT06172127)

🧪 Interventions in This Study

• Trastuzumab deruxtecan (DRUG)
• Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection (DRUG)
• Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• Dana-Farber Cancer Institute — Boston, Massachusetts
• Northwell Health — New York, New York
• Institute Paoli Calmettes — Marseille,
• Hopital Europeen Georges Pompidou — Paris,
• Hôpital Tenon AP-HP — Paris,
• Marienhospital Bottrop GmbH Klinik für Gynäkologie und Geburtshilfe — Bottrop,
• Kliniken Essen Mitte — Essen,
• Mammazentrum HH — Hamburg,
• Klinikum der Universität München — München,
• Humanitas Gavazzeni — Bergamo,
• Instituto Europeo di Oncologia — Milan,
• University Hospital Maggiore della Carita — Novara,
• Fondazione Policlinico Universitario Agostino Gemelli — Roma,
• Hospital Universitario Virgen del Rocío — Seville, Sevilla
• Hospital del Vinalopó — Alicante,
• Hospital General Universitario Dr. Balmis (Alicante) — Alicante,
• Hospital Clínic i Provincial de Barcelona — Barcelona,
• Hospital Universitari Dexeus — Barcelona,
• Institut Català d' Oncologia L'Hospitalet (ICO) — Barcelona,
• Hospital Universitario de Basurto — Bilbao,
• Hospital Provincial de Castellón — Castellon,
• Hospital Universitario Reina Sofía — Córdoba,
• Hospital Universitario Clínico San Cecilio de Granada — Granada,
• Hospital Universitario de León — León,
• Hospital Beata María Ana — Madrid,

📞 Contact the Study Coordinator

Phone: (877) 338-7425

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HER2-positive Breast Cancer

• Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease — Tampa, Florida
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] — Los Angeles, California
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — Plantation, Florida
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Mobile, Alabama
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Stamford, Connecticut

Explore by condition: All HER2-positive Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.